市場調查報告書

全球照護現場(POC)分子診斷市場:成長,趨勢,及預測

Point-of-Care Molecular Diagnostics Market - Growth, Trends, and Forecast (2020 - 2025)

出版商 Mordor Intelligence LLP 商品編碼 922063
出版日期 內容資訊 英文 110 Pages
商品交期: 2-3個工作天內
價格
全球照護現場(POC)分子診斷市場:成長,趨勢,及預測 Point-of-Care Molecular Diagnostics Market - Growth, Trends, and Forecast (2020 - 2025)
出版日期: 2020年01月01日內容資訊: 英文 110 Pages
簡介

本報告提供全球照護現場(POC)分子診斷市場的相關調查,市場機會和趨勢,成長及阻礙因素,各用途、技術、終端用戶、地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 簡介

  • 調查成果
  • 調查的前提條件
  • 調查範圍

第2章 調查方法

第3章 摘要整理

第4章 市場動態

  • 市場概況
  • 市場成長要素
    • 感染疾病和癌症增加的盛行率
    • 照護現場診斷的需求高漲
    • 技術和基因藥理學(醫藥基因學)的最近的進步
  • 市場阻礙因素
    • 不確實的償付方案
    • 複雜性高的檢驗設施的必要性
  • 波特的五力分析

第5章 市場區隔

  • 各用途
    • 感染疾病
    • 腫瘤學
    • 血液學
    • 產前檢查
    • 內分泌學
    • 其他的用途
  • 各技術
    • PCR
    • 遺傳基因排列
    • 雜合反應
    • 微陣列
  • 各終端用戶
    • 醫院
    • 居家護理
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲
    • 南美

第6章 競爭情形

  • 企業簡介
    • Abbott Laboratories
    • Bayer Healthcare
    • F. Hoffmann-La Roche Ltd.
    • Bio-Rad Laboratories
    • Danaher Corporation
    • BioMerieux
    • Dako
    • Abaxis Inc.
    • OraSure Technologies Inc.
    • Qiagen

第7章 市場機會及今後趨勢

目錄
Product Code: 67594

Market Overview

Point-of-Care (POC) Molecular testing enables physicians to improve the standard of care by combining quick diagnosis with treatment decision in the first visit by the patient instead of hours and days to have the test results. This would help prescribe treatment in the first instance without having to wait for the final results. In past decades, the prevalence of infectious diseases and chronic illnesses like cancer have increased. This has led to an increase in demand for novel diagnostic methods, which has led to progress in technological advancements and pharmacogenomics. This has also increased the demand for POC testing. These factors have helped the growth of the POC molecular testing market.

However, uncertain reimbursement scenarios have dissuaded many manufacturers to enter the market. Also, the lack of high-complexity test centers to use POC molecular testing have also hindered the market growth.

Scope of the Report

Point of care Molecular tests check for certain changes in a gene or chromosome that may cause or affect the chance of developing a specific disease or disorder, such as cancer, at or near the point of care, that is, at the time and place of patient care.

Key Market Trends

Application in Oncology is Expected to Register a High CAGR

Cancer Research UK suggests that the population suffering from cancer is expected to increase in the future. As per the report, if recent trends in the incidence of major cancers and population growth are consistent, it is predicted there will be 27.5 million new cancer cases worldwide each year by 2040. This is an increase of 61.7% from 17 million new cancer cases worldwide in 2018.

Many current point-of-care (POC) diagnostics utilize lateral flow immunoassay based technologies. Lateral flow immunoassays are devices that incorporate antibodies to detect the presence of an analyte like cancer biomarkers. In principle, a lateral flow test is a device that will provide a qualitative answer to the presence of a biomarker in a short period of time. Hence, the demand for these quick detection tests is expected to increase as the incidence of cancer increases.

North America is Expected to Dominate the Market

The prevalence of cancer in the United States is one of the highest in North American countries like the United States (US) and Mexico. According to a 2018 report by the National Cancer Institute, the incidence of cancer in the US is 439.2 per 100,000 men and women per year. The prevalence of the infectious disease is also high in the United States and Mexico. This has created a high demand for point-of-care diagnostics tests.

However, the United States has a developed and well-structured health care system. The system also encourages research and development. These policies encourage global players to enter the US, and eventually the North American market. As a result, this region enjoys the presence of many global market players. As high demand is met by the presence of global players in the region, the market is further expected to increase.

Competitive Landscape

The majority of the point of care molecular diagnostic tests are being manufactured by the global key players. Market leaders with more funds for research and a better distribution system have established their position in the market. Moreover, Asia-pacific is witnessing the emergence of some small players due to the rise of awareness. This has also helped the market to grow.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Prevalence of Infectious Diseases and Cancer
    • 4.2.2 Rising Demand for Point-of-care Diagnostics
    • 4.2.3 Recent Advancements in Technology and Pharmacogenomics
  • 4.3 Market Restraints
    • 4.3.1 Uncertain Reimbursement Scenario
    • 4.3.2 Need for High-complexity Testing Centers
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Application
    • 5.1.1 Infectious Diseases
    • 5.1.2 Oncology
    • 5.1.3 Hematology
    • 5.1.4 Prenatal Testing
    • 5.1.5 Endocrinology
    • 5.1.6 Other Applications
  • 5.2 By Technology
    • 5.2.1 PCR
    • 5.2.2 Genetic Sequencing
    • 5.2.3 Hybridization
    • 5.2.4 Microarray
  • 5.3 By End-User
    • 5.3.1 Hospitals
    • 5.3.2 Homecare
    • 5.3.3 Others
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Abbott Laboratories
    • 6.1.2 Bayer Healthcare
    • 6.1.3 F. Hoffmann-La Roche Ltd.
    • 6.1.4 Bio-Rad Laboratories
    • 6.1.5 Danaher Corporation
    • 6.1.6 BioMerieux
    • 6.1.7 Dako
    • 6.1.8 Abaxis Inc.
    • 6.1.9 OraSure Technologies Inc.
    • 6.1.10 Qiagen

7 MARKET OPPORTUNITIES AND FUTURE TRENDS